Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk
Aki T. Chaffin, … , Michael L. Goodson, Karen K. Ryan
Aki T. Chaffin, … , Michael L. Goodson, Karen K. Ryan
Published August 23, 2022
Citation Information: JCI Insight. 2022;7(19):e155848. https://doi.org/10.1172/jci.insight.155848.
View: Text | PDF
Research Article Endocrinology Hepatology

FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk

  • Text
  • PDF
Abstract

The liver regulates energy partitioning and use in a sex-dependent manner, coupling hepatic substrate availability to female reproductive status. Fibroblast growth factor 21 (FGF21) is a hepatokine produced in response to metabolic stress that adaptively directs systemic metabolism and substrate use to reduce hepatic lipid storage. Here we report that FGF21 altered hepatic transcriptional and metabolic responses, and reduced liver triglycerides, in a sex-dependent manner. FGF21 decreased hepatic triglycerides in obese male mice in a weight loss–independent manner; this was abrogated among female littermates. The effect of FGF21 on hepatosteatosis is thought to derive, in part, from increased adiponectin secretion. Accordingly, plasma adiponectin and its upstream adrenergic receptor → cAMP → exchange protein directly activated by cAMP signaling pathway was stimulated by FGF21 in males and inhibited in females. Both ovariectomized and reproductively senescent old females responded to FGF21 treatment by decreasing body weight, but liver triglycerides and adiponectin remained unchanged. Thus, the benefit of FGF21 treatment for improving hepatosteatosis depends on sex but not on a functional female reproductive system. Because FGF21 provides a downstream mechanism contributing to several metabolic interventions, and given its direct clinical importance, these findings may have broad implications for the targeted application of nutritional and pharmacological treatments for metabolic disease.

Authors

Aki T. Chaffin, Karlton R. Larson, Kuei-Pin Huang, Chih-Ting Wu, Nadejda Godoroja, Yanbin Fang, Devi Jayakrishnan, Karla A. Soto Sauza, Landon C. Sims, Niloufar Mohajerani, Michael L. Goodson, Karen K. Ryan

×

Figure 6

Reproductive status influences the sex-dependent control of energy balance, but not hepatosteatosis, by FGF21.

Options: View larger image (or click on image) Download as PowerPoint
Reproductive status influences the sex-dependent control of energy balan...
In DIO male, OVX female, and sham-operated female mice, FGF21 treatment decreased body weight in a sex- and reproductive status–dependent manner, such that OVX females phenocopied the male response (A and B). FGF21 altered food intake (C), and feed efficiency mirrored changes in body weight change (D). As expected, FGF21 decreased hepatic triglycerides in males but not sham-operated females. FGF21 did not reduce liver triglycerides in OVX females despite significant FGF21-induced weight loss (E). Consistent with this, FGF21 altered plasma adiponectin in a sex- and reproductive status–dependent manner. FGF21 increased adiponectin in males, decreased adiponectin in sham-operated females, and had no effect in OVX females (F). In a separate experiment, we tested the possibility of a “floor effect” for treating hepatosteatosis in DIO females. Female mice were maintained on high-fat diet to induce obesity and hepatosteatosis. Next, half the mice were briefly switched to a chow diet. Chow diet “treatment” significantly reduced body weight (G and H) and hepatic triglycerides (I). Analyses made by 3-way ANOVA, Tukey post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (A–F, n = 10–12 mice/group); t test, ###P < 0.001 (E–G, n = 10 mice/group). Data are shown as mean ± SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts